Pharmalytics GroupPharmalytics Group

Publications

Research that advances evidence, methods, and reimbursement decision-making.

A selection of peer-reviewed publications from our team spanning health technology assessment policy, evidence synthesis, comparative effectiveness, health economics, real-world evidence, and market access—including research informed by [hta]DataMine™ and other applied evidence programs.

Full publication record

Our senior team’s complete publication history on policy topics and applied methodologies is indexed on PubMed.

View on PubMed

  1. J Comp Eff Res

    Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience.

    Balijepalli C, Gullapalli L, Prasad S, Paul Roc N, Rusu A, Price N, Dempster W, Barakat S.

    DOI: 10.57264/cer-2025-0024

  2. Value in Health

    Estimating Epidemiological Estimates of Rare Diseases in Reimbursement Submissions to Canada's Drug Agency: A Comparison of Approaches in the Absence of Local Real-World Data.

    Druyts E, Gullapalli L, Balijepalli C.

    DOI: 10.1016/j.jval.2025.04.543

  3. Target Oncol

    Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall Survival.

    Schmidinger M, Rane PP, Yan K, Druyts E, Burgents J, Sundaram M, Peer A.

    DOI: 10.1007/s11523-025-01147-3

  4. J Comp Eff Res

    The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.

    Balijepalli C, Gullapalli L, Joshy J, Rawson NB.

    DOI: 10.57264/cer-2023-0178

  5. Value in Health

    Is There Value in Utilizing Country-Specific Health Utility Values for Health Technology Assessment Submissions? Findings From a Case Study in Hematological Cancers.

    Yan K, Druyts E, Gullapalli L, Sharma A, Balijepalli C.

    DOI: 10.1016/j.jval.2024.10.1863

  6. Value in Health

    A Review of Real-World Evidence in Non-Oncology Submissions Made to Four Health Technology Assessment (HTA) Agencies.

    Balijepalli C, Li J, Ferrazzi S, Mathers E, Gullapalli L, Awan A.

    DOI: 10.1016/j.jval.2024.03.1401

  7. Value in Health

    Assessing Relationships Between the CADTH Revised ICERs and Unmet Need, Clinical Benefit, Price Reductions, and Listing Negotiation Timelines.

    Balijepalli C, Li J, Ferrazzi S, Mathers E, Gullapalli L, Awan A.

    DOI: 10.1016/j.jval.2024.03.1418

  8. Value in Health

    Type of Clinical Evidence and Its Impact on Price Reductions for Oncology Drugs: A Review of Reimbursement Submissions in Canada.

    Balijepalli C, Gullapalli L, Yan K, Sharma A, Druyts E, Rawson N.

    DOI: 10.1016/j.jval.2024.10.1997

  9. Curr Med Res Opin

    Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review.

    Yan K, Balijepalli C, Gullapalli L, Joshy J, Kotum S, Druyts E.

    DOI: 10.1080/03007995.2024.2395435

  10. Curr Med Res Opin

    Humanistic burden of mucopolysaccharidoses: a systematic literature review.

    Li JW, Yan K, Balijepalli C, Druyts E.

    DOI: 10.1080/03007995.2024.2316213

  11. Kidney Cancer

    Efficacy, Effectiveness, and Safety of Interventions for Von Hippel-Lindau Associated Renal Cell Carcinoma: A Systematic Literature Review.

    Jonasch E, Balijepalli C, Yan K, Gullapalli L, Li J, Sundaram M.

    DOI: 10.3233/KCA-230021

  12. Value in Health

    Modeling Approaches in the Cost-Effectiveness Analysis of Cancer Treatments: A Review of Submissions Made to the Canadian Agency for Drugs and Technologies in Health.

    Balijepalli C, Joshy J, Gullapalli L, Yan K.

    DOI: 10.1016/j.jval.2023.03.2490

  13. Melanoma Res

    Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions.

    Shui IM, Scherrer E, Frederickson A, Li JW, Mynzhassarova A, Druyts E, Tawbi H.

    DOI: 10.1097/CMR.0000000000000850

  14. Curr Med Res Opin

    Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.

    Bischof M, Lorenzi M, Lee J, Druyts E, Balijepalli C, Dabbous O.

    DOI: 10.1080/03007995.2021.1947216

  15. J Health Econ Outcomes Res

    Quality of Life in Wilson's Disease: A Systematic Literature Review.

    Balijepalli C, Yan K, Gullapalli L, Barakat S, Chevrou-Severac H, Druyts E.

    DOI: 10.36469/jheor.2021.29987

  16. Clinicoecon Outcomes Res

    Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the CADTH Common Drug Review.

    Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J.

    DOI: 10.2147/CEOR.S264589

Work with us.

We’d be glad to hear what you’re working on and explore how we can help.

Get in touch